The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis

2005 ◽  
Vol 11 (2) ◽  
pp. 175-181 ◽  
Author(s):  
Scott B Patten ◽  
Gordon Francis ◽  
Luanne M Metz ◽  
Maria Lopez-Bresnahan ◽  
Peter Chang ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Trials ◽  
Rating Scale ◽  
Suicide Attempts ◽  
Scale Scores ◽  
Symptom Ratings ◽  
Negative Findings ◽  
Ifn Therapy ◽  
Ifn Treatment ◽  
The Relationship

It has been suggested that interferons (IFN) may cause depressionde novo or worsen pre-existing depression. Depression data collected using validated instruments from individual clinical trials in multiple sclerosis, however, have consistently failed to identify an association. In this study, pooled data from 6 controlled studies and 17 noncontrolled clinical trials of subcutaneous IFN beta-1a were assessed to determine the relationship between IFN therapy with physician reports of depression and suicide. In distinction to the negative findings for depressive symptom ratings, pooling of physician-reported side effect data from these clinical trials identified a statistically significant association between depression and IFN use during the first six months of treatment. There was an association between these reported episodes of depression and discontinuation of IFN therapy, but IFN treatment was not associated with suicide attempts. IFN β-1a may induce a constellation of symptoms, particularly early in therapy, that may be labelled as depression by physicians. However, the lack of an increase in depression-rating scale scores and the lack of association with suicide risk suggests that the syndrome may be an atypical one.

scholarly journals An Exploratory Cohort Study of the Association between the Level of Testosterone and Suicidal Ideation in Hospitalized Adolescent Females with Depression in China

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Yan Liu ◽  
Shaohua Wang ◽  
Chuang Xue ◽  
Xiwen Hu ◽  
Guoling Zhou ◽  
...  
Keyword(s):  
Risk Factors ◽  
Cohort Study ◽  
Suicidal Ideation ◽  
Suicidal Behavior ◽  
Rating Scale ◽  
Suicide Attempts ◽  
Adolescent Females ◽  
Testosterone Levels ◽  
Scale Scores ◽  
The Relationship

Background. To date, around 4 per 100,000 adolescents committed suicide within the 29 OECD countries. The suicidal behavior is related to psychological factors, genetics, neurobiology, and other biomarkers. The aim of this study was to examine risk factors for the development of suicidal ideation in adolescent females with depression, focusing on the relationship between different testosterone levels and suicidal ideation, in order to help develop strategies to intervene in suicidal behavior in female adolescents with depression. Method. In this single-center prospective cohort study, we enrolled adolescent females with depression. We collected information on their baseline data, testosterone levels, symptom self-rating scale scores, suicidal ideation, non-suicidal self-injurious (NSSI) behaviours, and suicide attempts. We used multivariate logistic regression to identify risk factors for the development of suicidal ideation in adolescent females with depression. Results. A total of 113 hospitalized adolescent females were enrolled with a mean age of 13.5 (1.20). Among these patients, there were 86 (76.11%) subjects who suffered from suicidal ideation, 59 (52.21%) had NSSI and 23 (20.35%) had suicide attempt behavior. In the final model, higher level of testosterone ( p = 0.04 ) and higher age ( p = 0.02 ) were associated with the higher odds of having suicidal ideation. Conclusion. In this exploratory cohort study, the emergence of suicidal ideation was common among adolescent females with depression. This study is consistent with the other studies. It shows that the age is a potential predictor for suicidal ideation in hospitalized adolescent females with depression.

Association of Progressive Supranuclear Palsy Rating Scale with Progressive Supranuclear Palsy Quality of Life Scale

2021 ◽  
pp. 1-8
Author(s):  
Alexander Pantelyat ◽  
Lenora Higginbotham ◽  
Liana Rosenthal ◽  
Diane Lanham ◽  
Vanessa Nesspor ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Clinical Trials ◽  
Progressive Supranuclear Palsy ◽  
Rating Scale ◽  
Linear Regression Analysis ◽  
Disease Evolution ◽  
Quality Of Life Scale ◽  
Patient Reported ◽  
Scale Scores

<b><i>Introduction:</i></b> There is growing interest in using patient-reported outcomes as end points in clinical trials, such as the progressive supranuclear palsy quality of life (PSP-QoL) scale. However, this tool has not been widely validated and its correlation with validated motor scales has not been explored. To evaluate the potential utility of using PSP-QoL as an outcome, it is important to examine its relationship with a standard scale used to evaluate neurologic parameters, such as the PSP Rating Scale. <b><i>Methods:</i></b> PSP-QoL and PSP Rating Scale scores were gathered from 60 clinically diagnosed PSP patients, including patients with Richardson syndrome PSP (PSP-RS, <i>n</i> = 43) and those with non-RS PSP variants (<i>n</i> = 17). Linear regression analysis adjusted for age, sex, and disease duration was used to evaluate the cross-sectional relationship between the total and subscale scores of the 2 instruments. <b><i>Results:</i></b> Among 60 PSP patients, there was a significant correlation between total PSP-QoL and PSP Rating Scale scores. The physical and mentation subscales of each instrument also demonstrated significant correlations. Comparisons among PSP subtypes indicated that worsening PSP-QoL Total and Physical subscale scores correlated with worsening PSP Rating Scale gait subscale scores more strongly for the non-RS PSP variants than for PSP-RS. <b><i>Discussion:</i></b> There is a significant association between the total scores and many of the subscale scores of the PSP-QoL and the PSP Rating Scale. Additionally, the relationship between these measures may differ for PSP-RS and non-RS variants. These findings suggest that the PSP-QoL may be useful in clinical trials as a patient-reported outcome measure. Large prospective multicenter studies utilizing the PSP-QoL are necessary to examine its relationship to disease evolution and changes in the PSP Rating Scale.

Optic Neuritis Revisited

2006 ◽  
Vol 8 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Fiona Costello
Keyword(s):  
Magnetic Resonance Imaging ◽  
Multiple Sclerosis ◽  
Clinical Trials ◽  
Optic Neuritis ◽  
Large Scale ◽  
Inflammatory Process ◽  
Resonance Imaging ◽  
Prognostic Information ◽  
Future Risk ◽  
The Relationship

Optic neuritis (ON) refers to a retrobulbar inflammatory process of the optic nerve and frequently manifests as the first clinical symptom of multiple sclerosis (MS). The diagnosis is established on clinical grounds and is complemented by magnetic resonance imaging, which provides prognostic information about the future risk of MS. The results of large-scale clinical trials have enhanced understanding of the relationship between ON and MS.

scholarly journals Dichotomizing rating scale scores in psychiatry: a bad idea?

2012 ◽  
Vol 22 (1) ◽  
pp. 17-19 ◽  
Author(s):  
M. Purgato ◽  
C. Barbui
Keyword(s):  
Clinical Trials ◽  
Systematic Reviews ◽  
Rating Scales ◽  
Rating Scale ◽  
Outcome Data ◽  
Continuous Outcome ◽  
Advantages And Disadvantages ◽  
Continuous Outcomes ◽  
Scale Scores

In psychiatry, the use of rating scales as measures of outcome in clinical trials allows us to generate continuous outcome data, where each individual's outcome is measured in numbers. Continuous outcomes can be divided into two categories, such as improved and not improved, or may be kept continuous. This article briefly presents the main advantages and disadvantages of these two approaches, which are commonly employed in the analyses of rating scale scores in clinical trials and systematic reviews.

Correlation Between Depression and Interferon-Beta Therapy in Patients with Multiple Sclerosis: A Systematic Review

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1 ◽  
Author(s):  
I. Zervas ◽  
C. Mitsonis ◽  
N. Dimopoulos ◽  
V. Psarra ◽  
C. Potagas ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Suicide Attempts ◽  
Antidepressant Treatment ◽  
Life Time ◽  
Treatment Programs ◽  
Literature Searches ◽  
Patient Reported ◽  
History Of ◽  
Ifn Therapy

Introduction:Depression is the most frequent psychiatric disorder encountered in patients with Multiple Sclerosis (MS), with a life-time prevalence of approximately 50%. INF-beta (INF-β) shows beneficial effect on the course of MS. Although it has been suggested that interferons may be associated to depression, the validity and the nature of this relationship remain unclear regarding INF-β. The objective of this study is to review the scientific literature in order to elucidate the relationship between depression and INF-β therapy.Methods:This systematic review was based on Medline, Embase and, PsycLIT literature searches (through January 2005), supplemented by bibliographical citations in identified papers.Results:The majority of studies ruled out a correlation between INF-β1a/1b and depression in MS patients. However, patients with a recent history of depression may be at higher risk for depression particularly in the early phase of treatment (first 6 months), even if they are not depressed at the initiation of medication. There is an association between depressive symptoms and discontinuation of INF therapy but INF-β does not seem to be associated with suicide attempts. Treating patient-reported depression increases adherence to treatment.Conclusions:Clinicians should not refrain from including patients with MS in INF-β treatment programs, even those with depression in the past or at the present time. Screening, monitoring, and early antidepressant treatment is necessary to optimize IFN therapy for the majority of patients with MS.

scholarly journals Predicting therapeutic response to oral ketamine for chronic suicidal ideation: a Bayesian network for clinical decision support

2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Denise Beaudequin ◽  
Adem T. Can ◽  
Megan Dutton ◽  
Monique Jones ◽  
Cyrana Gallay ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Suicidal Ideation ◽  
Bayesian Network ◽  
Roc Curve ◽  
Suicide Ideation ◽  
Rating Scale ◽  
Suicide Attempts ◽  
Depression Symptoms ◽  
Oral Ketamine ◽  
Pre Treatment

Abstract Background The glutamatergic modulator ketamine has been shown to result in rapid reductions in both suicidal ideation (SI) and depressive symptoms in clinical trials. There is a practical need for identification of pre-treatment predictors of ketamine response. Previous studies indicate links between treatment response and body mass index (BMI), depression symptoms and previous suicide attempts. Our aim was to explore the use of clinical and demographic factors to predict response to serial doses of oral ketamine for chronic suicidal ideation. Methods Thirty-two participants completed the Oral Ketamine Trial on Suicidality (OKTOS). Data for the current study were drawn from pre-treatment and follow-up time-points of OKTOS. Only clinical and sociodemographic variables were included in this analysis. Data were used to create a proof of concept Bayesian network (BN) model of variables predicting prolonged response to oral ketamine, as defined by the Beck Scale for Suicide Ideation (BSS). Results The network of potential predictors of response was evaluated using receiver operating characteristic (ROC) curve analyses. A combination of nine demographic and clinical variables predicted prolonged ketamine response, with strong contributions from BMI, Social and Occupational Functioning Assessment Scale (SOFAS), Montgomery-Asberg Depression Rating Scale (MADRS), number of suicide attempts, employment status and age. We evaluated and optimised the proposed network to increase the area under the ROC curve (AUC). The performance evaluation demonstrated that the BN predicted prolonged ketamine response with 97% accuracy, and AUC = 0.87. Conclusions At present, validated tools to facilitate risk assessment are infrequently used in psychiatric practice. Pre-treatment assessment of individuals’ likelihood of response to oral ketamine for chronic suicidal ideation could be beneficial in making more informed decisions about likelihood of success for this treatment course. Clinical trials registration number ACTRN12618001412224, retrospectively registered 23/8/2018.

scholarly journals A clinical study comparing manic and mixed episodes in patients with bipolar disorder

2007 ◽  
Vol 29 (2) ◽  
pp. 130-133 ◽  
Author(s):  
Ângela Maria Schwartzmann ◽  
José Antonio Amaral ◽  
Cilly Issler ◽  
Sheila C Caetano ◽  
Renata S Tamada ◽  
...  
Keyword(s):  
Rating Scale ◽  
Suicide Attempts ◽  
Psychotic Symptoms ◽  
Global Assessment Scale ◽  
Young Mania ◽  
Manic Symptoms ◽  
Characteristics Method ◽  
Scale Scores ◽  
Dsm Iv ◽  
Manic Patients

OBJECTIVE: Mixed episodes have been described as more severe than manic episodes, especially due to their longer duration and their association with higher rates of suicide attempts, hospitalization and psychotic symptoms. The purpose of this study was to compare the severity between mixed and pure manic episodes according to DSM-IV criteria, through the evaluation of sociodemographic data and clinical characteristics. METHOD: Twenty-nine bipolar I patients presenting acute mixed episodes were compared to 20 bipolar I patients with acute manic episodes according to DSM-IV criteria. We analyzed (cross-sectionally) episode length, presence of psychotic symptoms, frequency of suicide attempts and hospitalization, Young Mania Rating Scale scores, Hamilton Depression Rating Scale scores and the Clinical Global Assessment Scale scores. RESULTS: Young Mania Rating Scale scores were higher in manic episodes than in mixed episodes. There were no differences in gender frequency, CGI scores and rates of hospitalization, suicide attempts and psychotic symptoms, when mixed and manic episodes where compared. Patients with mixed episodes were younger. CONCLUSION: In our sample, mixed states occurred at an earlier age than manic episodes. Contrary to previous reports, we did not find significant differences between manic and mixed episodes regarding severity of symptomatology, except for manic symptoms ratings, which were higher in acute manic patients. In part, this may be explained by the different criteria adopted on previous studies.

Adolescents’ self-mutilation - Relationship with dependent behaviour

2003 ◽  
Vol 62 (4) ◽  
pp. 241-249 ◽  
Author(s):  
M. Bolognini ◽  
B. Plancherel ◽  
J. Laget ◽  
P. Stéphan ◽  
O. Halfon
Keyword(s):  
Suicide Attempts ◽  
Clinical Sample ◽  
Control Sample ◽  
Clinical Population ◽  
Control Group ◽  
Clinical Group ◽  
Self Mutilation ◽  
Self Harm ◽  
Partial Overlap ◽  
The Relationship

The aim of this study, which was carried out in the French-speacking part of Switzerland, was to examine the relationship between suicide attempts and self-mutilation by adolescents and young adults. The population, aged 14-25 years (N = 308), included a clinical sample of dependent subjects (drug abuse and eating disorders) compared to a control sample. On the basis of the Mini Neuropsychiatric Interview ( Sheehan et al., 1998 ), DSM-IV criteria were used for the inclusion of the clinical population. The results concerning the occurrence of suicide attempts as well as on self-mutilation confirm most of the hypotheses postulated: suicidal attempts and self-mutilation were more common in the clinical group compared to the control group, and there was a correlation between suicide attempts and self-mutilation. However, there was only a partial overlap, attesting that suicide and self-harm might correspond to two different types of behaviour.

Investigating the Relationship Between Self-Esteem and Stigma Among Young Adults With History of Suicide Attempts

Crisis ◽  
2016 ◽  
Vol 37 (4) ◽  
pp. 265-270 ◽  
Author(s):  
Meshan Lehmann ◽  
Matthew R. Hilimire ◽  
Lawrence H. Yang ◽  
Bruce G. Link ◽  
Jordan E. DeVylder
Keyword(s):  
Young Adults ◽  
Suicide Attempts ◽  
Self Esteem ◽  
High Risk Population ◽  
High Functioning ◽  
People With Mental Illness ◽  
History Of ◽  
The Individual ◽  
The Impact ◽  
The Relationship

Abstract. Background: Self-esteem is a major contributor to risk for repeated suicide attempts. Prior research has shown that awareness of stigma is associated with reduced self-esteem among people with mental illness. No prior studies have examined the association between self-esteem and stereotype awareness among individuals with past suicide attempts. Aims: To understand the relationship between stereotype awareness and self-esteem among young adults who have and have not attempted suicide. Method: Computerized surveys were administered to college students (N = 637). Linear regression analyses were used to test associations between self-esteem and stereotype awareness, attempt history, and their interaction. Results: There was a significant stereotype awareness by attempt interaction (β = –.74, p = .006) in the regression analysis. The interaction was explained by a stronger negative association between stereotype awareness and self-esteem among individuals with past suicide attempts (β = –.50, p = .013) compared with those without attempts (β = –.09, p = .037). Conclusion: Stigma is associated with lower self-esteem within this high-functioning sample of young adults with histories of suicide attempts. Alleviating the impact of stigma at the individual (clinical) or community (public health) levels may improve self-esteem among this high-risk population, which could potentially influence subsequent suicide risk.

Sign in / Sign up

Export Citation Format

Share Document